DSS, INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
DSS$0.50+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
For the Years Ended December 31,
| Common Stock · Preferred Stock · Additional Paid-in · Accumulated · Total DSS · Non- controlling Interest in | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity · Subsidiary · Total | ||||||||||
| Balance, December 31, 2023 | 7,066,772 | $140,000 | - | $ | - | $319,963,000 | $(256,176,000) | $63,927,000 | $19,287,000 | $83,214,000 |
| - | ||||||||||
| Issuance of common stock, net of expenses | 1,025,746 | 20,000 | - | - | 980,000 | - | 1,000,000 | - | 1,000,000 | |
| Stock based payments | - | - | - | 19,000 | - | 19,000 | - | 19,000 | ||
| Issuance of common stock, net of expenses - Impact BioMedical, Inc. | - | 1,000 | - | - | 1,890,000 | - | 1,891,000 | 298,000 | 2,189,000 | |
| Net loss | - | - | - | - | - | (46,896,000) | (46,896,000) | (6,810,000) | (53,706,000) | |
| Balance, December 31, 2024 | 8,092,518 | $161,000 | - | $ | - | $322,852,000 | $(303,072,000) | $19,941,000 | $12,775,000 | $32,716,000 |
| - | ||||||||||
| Balance, December 31, 2024 | 8,092,518 | 161,000 | - | - | 322,852,000 | (303,072,000) | 19,941,000 | 12,775,000 | 32,716,000 | |
| Issuance of common stock, net of expenses - Impact BioMedical, Inc. | - | 1,000 | - | - | 2,082,000 | - | 2,083,000 | 331,000 | 2,414,000 | |
| Issuance of common stock for award | 1,000,000 | 20,000 | - | - | 850,000 | - | 870,000 | - | 870,000 | |
| Stock based payments for professional services rendered for Impact Bio | - | - | - | - | 190,000 | - | 190,000 | - | 190,000 | |
| Stock based payments | - | - | - | - | 13,000 | - | 13,000 | - | 13,000 | |
| Net loss | - | - | - | - | - | (23,929,000) | (23,929,000) | (3,559,000) | (27,488,000) | |
| Balance, December 31, 2025 | 9,092,518 | $182,000 | - | $ | - | $325,987,000 | $(327,001,000) | $(832,000) | $9,547,000 | $8,715,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.